98%
921
2 minutes
20
Introduction: The prevalence of systemic sclerosis (SSc), as well as obesity, has significantly increased in recent decades. To address the lack of data on obese SSc patients, we conducted a retrospective comparative study to assess the prevalence, clinical characteristics, and long-term consequences of obesity in SSc patients.
Methods: We conducted a retrospective comparative study at the Cochin University Hospital's Department of Internal Medicine (Paris) from 2000 to 2019.
Results: Of the 911 SSc patients included, 90 (9.9%) were obese, comprising 79 females and 11 males. The median weight for obese patients was 90 [82-98] kg, compared to 60 [53-67] kg for non-obese patients, corresponding to a median body mass index of 33 [31-37] kg/m and 23 [20-25] kg/m, respectively. Obese patients exhibited a higher prevalence of cardiovascular risk factors. The median modified Rodnan skin score was significantly higher in non-obese patients than in obese patients (6 [2-16] vs 3 [2-7]; P<0.05). Organ involvement did not differ significantly between obese and non-obese patients. We observed a lower number of deaths in obese SSc patients compared to non-obese SSc patients (6 [11%] vs. 26 deaths [25%], P=0.06). Analysis of 30-year Kaplan Meier survival curves did not show significant survival difference between obese and non-obese SSc patients.
Conclusions: This study of obese ScS patients reveals that they have a higher prevalence of cardiovascular risk factors, lower mRSS, less calcinosis, and similar rates of organ damage and mortality compared to non-obese ScS patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.revmed.2025.04.026 | DOI Listing |
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
Rev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).
View Article and Find Full Text PDFSpine (Phila Pa 1976)
October 2025
Department of Orthopaedic Surgery, Rothman Orthopaedic Institute at Thomas Jefferson University Hospital, Philadelphia, PA.
Study Design: Retrospective cohort.
Objective: To evaluate the impact of having a history of obstructive sleep apnea (OSA) in patients undergoing anterior cervical discectomy and fusion (ACDF) on postoperative outcomes.
Background: With an aging population and rates of obesity increasing, comorbidities that influence patient safety are increasingly common.
Cancer
September 2025
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: The influence of obesity and sex on outcomes in pancreatic adenocarcinoma (PDAC) remains unclear. The association between obesity (body mass index [BMI], ≥30) and biologic sex (male or female) for outcomes in patients with PDAC undergoing a surgery-first approach was investigated.
Methods: A prospectively maintained pancreatic cancer database at the Memorial Sloan Kettering Cancer Center was queried to identify all patients undergoing surgery with a pathologic diagnosis of PDAC.